Evidence map›Paper›PMID 30945473›Full record

ArticleCancer medicine2019

Impact of serious mental illness on the treatment and mortality of older patients with locoregional high-grade (nonmetastatic) prostate cancer: retrospective cohort analysis of 49 985 SEER-Medicare patients diagnosed between 2006 and 2013.

Dennis A Fried, Hossein Sadeghi-Nejad, Dian Gu, Shouhao Zhou, Weiguo He, Sharon H Giordano, Sri Ram Pentakota, Kitaw Demissie, Drew Helmer, Chan Shen

Open access · goldAbstract readHistorical Article
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. The Risk and The Course of Cancer Among People with Severe Mental Illness.Clinical practice and epidemiology in mental health : CP & EMH · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Dennis A FriedWar Related Illness and Injury Study Center, VA-New Jersey Healthcare System, East Orange, New Jersey.ORCID 0000-0003-3517-0758
Hossein Sadeghi-NejadVA New Jersey Health Care System, East Orange, New Jersey.
Dian GuMD Andersen Cancer Center, University of Texas, Houston, Texas.
Shouhao ZhouMD Andersen Cancer Center, University of Texas, Houston, Texas.
Weiguo HeMD Andersen Cancer Center, University of Texas, Houston, Texas.
Sharon H GiordanoMD Andersen Cancer Center, University of Texas, Houston, Texas.
Sri Ram PentakotaDepartment of Epidemiology, Rutgers, The State University of New Jersey, Newark, New Jersey.
Kitaw DemissieDepartment of Epidemiology, Rutgers, The State University of New Jersey, Newark, New Jersey.
Drew HelmerWar Related Illness and Injury Study Center, VA-New Jersey Healthcare System, East Orange, New Jersey.
Chan ShenMD Andersen Cancer Center, University of Texas, Houston, Texas.
The University of Texas MD Anderson Cancer Center · USRutgers, The State University of New Jersey · USVA New Jersey Health Care System · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundThe influence of serious mental illness (SMI) on the treatment and survival of patients with high-grade prostate cancer is not well understood. We compared the initial cancer treatment and cancer-specific mortality of SEER-Medicare patients with locoregional high-grade (nonmetastatic) prostate cancer with and without preexisting SMI.

methodsWe identified SEER-Medicare patients who were 67 years of age or older diagnosed between 2006 and 2013 with locoregional high-grade (nonmetastatic) prostate cancer. Preexisting SMI was identified by claims indicative of bipolar disorder, schizophrenia, and other psychotic disorder, during the 2 years before cancer diagnosis. We used multivariable binary logistic regression to examine associations between SMI and receipt of surgery or radiation concurrent with hormone therapy (definitive initial treatment) within 1 year after cancer diagnosis. We used Kaplan-Meier survival curves, as well as Cox proportional hazards and competing risk models to evaluate unadjusted and adjusted associations between SMI and 5-year cancer-specific survival.

resultsAmong 49 985 patients with locoregional high-grade (nonmetastatic) prostate cancer, 523 (1.1%) had SMI and 49 462 (98.9%) had no SMI. Overall, SMI was associated with reduced odds of receiving surgery (OR = 0.66, 95% CI: 0.49-0.89) or radiation concurrent with hormone therapy (OR = 0.81, 95% CI: 0.67-0.98) as initial treatments in the year after cancer diagnosis. Additionally, SMI was associated with higher hazard of 5-year cancer-specific death (HR = 1.41, 95% CI: 1.06-1.89) after accounting for competing risks of non-cancer death.

conclusionAmong SEER-Medicare patients with locoregional high-grade (nonmetastatic) prostate cancer, those with preexisting SMI-relative to those without these conditions-were less likely to receive definitive initial treatment in the year after diagnosis and had poorer cancer-specific survival 5 years after diagnosis.

Indexed as

History, 21st CenturyHumansKaplan-Meier EstimateMaleMedicareMental DisordersMortalityNeoplasm GradingNeoplasm StagingProportional Hazards ModelsProstatic NeoplasmsRetrospective StudiesSEER ProgramUnited States

Identifiers

PMID30945473
PMCPMC6536920
OpenAlexW2928195609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.